ALX Oncology (ALXO) : Evorpacept Data Fails To Impress At ASH Presentation

•  Announced initial data from the its Phase 1/2 ASPEN-02 study of evorpacept in combination with azacitidine for the treatment of patients with previously untreated higher-risk or relapsed or refractory myelodysplastic syndrome. The combination was well tolerated; among efficacy results, in six previously untreated HR MDS response-evaluable patients, three patients achieved an objective response and two achieved stable disease. Trades at record lows.